Evidence suggests that reduced CTR1 expression in cancer cells contributes to resistance against platinum-based drugs, whereas enhanced expression sensitizes cells to these therapies (Tsimberidou et al., 2015; Skowron et al., 2018; Kim et al., 2014; Kuo et al., 2021). This evidence concerns the gene SLC31A1 and cancer.